Ukimura Osamu, Kawauchi Akihiro, Fujito Akira, Mizutani Yoichi, Okihara Koji, Mikami Kazuya, Soh Jintetsu, Nakamura Terukazu, Nakanishi Hiroyuki, Ushijima So, Miki Tsuneharu
Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto 602-8566, Japan.
Int J Urol. 2004 Dec;11(12):1051-7. doi: 10.1111/j.1442-2042.2004.00966.x.
Although radio-frequency ablation (RFA) has been recently applied as a minimally invasive treatment option for renal cell carcinoma (RCC), indication of this modality remains a critical issue due to the lack of complete tumor destruction as well as the uncertainty of its long-term efficacy. We report the efficacy of RFA for nine carefully selected patients with RCC who had significant reason to avoid invasive surgical treatment under general anesthesia.
Radio-frequency ablation was performed under epidural or local anesthesia by ultrasound or computed tomography (CT) guidance in nine patients with biopsy proven RCC (mean diameter, 38 mm; range, 20-53 mm), who were at significant operative or anesthetic risk for invasive surgery. Follow-up enhanced CT scans or magnetic resonance images were evaluated every 3-6 months and an evaluation of metastasis was performed every 6 months.
At a mean follow-up of 17 months, seven (78%) of the nine patients with renal tumor showed no tumor enhancement. The renal function of all patients was well preserved. All patients were able to continue undergoing their respective treatments for active diseases in other organs in parallel to the RFA treatment. No distant metastasis, urine leakage were reported and one case of temporary hematuria and one case of peri-renal hemorrhage not requiring blood transfusion were encountered. Intra-operative ultrasonography was useful in the real-time monitoring of the minimally excessive extension of ablation into the normal parenchyma.
Radio-frequency ablation appears to be an effective and safe minimally invasive therapeutic option for selected patients with RCC who have reason to avoid invasive surgery under general anesthesia.
尽管射频消融(RFA)最近已被用作肾细胞癌(RCC)的微创治疗选择,但由于缺乏对肿瘤的完全破坏以及其长期疗效的不确定性,这种治疗方式的适应证仍然是一个关键问题。我们报告了RFA对9例精心挑选的RCC患者的疗效,这些患者有充分理由避免在全身麻醉下进行侵入性手术治疗。
对9例经活检证实为RCC(平均直径38mm;范围20 - 53mm)且有显著手术或麻醉风险而无法进行侵入性手术的患者,在硬膜外或局部麻醉下,通过超声或计算机断层扫描(CT)引导进行射频消融。每3 - 6个月评估随访增强CT扫描或磁共振成像,每6个月进行转移评估。
平均随访17个月时,9例肾肿瘤患者中有7例(78%)肿瘤无强化。所有患者的肾功能均得到良好保留。所有患者在接受RFA治疗的同时,能够继续接受针对其他器官活动性疾病的各自治疗。未报告远处转移、尿漏,仅遇到1例暂时性血尿和1例无需输血的肾周出血。术中超声有助于实时监测消融对正常实质的最小过度扩展。
对于有理由避免在全身麻醉下进行侵入性手术的特定RCC患者,射频消融似乎是一种有效且安全的微创治疗选择。